S6K1 blockade overcomes acquired resistance to EGFR-TKIs in non-small cell lung cancer

The development of resistance to EGFR Tyrosine kinase inhibitors (TKIs) in NSCLC with activating EGFR mutations is a critical limitation of this therapy. In addition to genetic alterations such as EGFR secondary mutation causing EGFR-TKI resistance, compensatory activation of signaling pathways with...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Oncogene
Egile Nagusiak: Shen, Hua, Wang, Gao-Chan, Li, Xiang, Ge, Xin, Wang, Meng, Shi, Zhu-Mei, Bhardwaj, Vikas, Wang, Zi-Xuan, Zinner, Ralph G., Peiper, Stephen C., Aplin, Andrew E., Jiang, Bing-Hua, He, Jun
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2020
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7718330/
https://ncbi.nlm.nih.gov/pubmed/33037411
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41388-020-01497-4
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak